Curiethérapie prostatique de haut débit de dose

P. Nickers; P. Blanchard; J. M. Hannoun-Lévi; A. Bossi; O. Chapet; S. Guérif

doi:10.1016/j.canrad.2013.02.005

Curiethérapie prostatique de haut débit de dose

P. Nickers, P. Blanchard, J. M. Hannoun-Lévi, A. Bossi, O. Chapet, S. Guérif

Résultats de recherche: Contribution à un journal › Brève enquête › Revue par des pairs

7 Citations (Scopus)

Résumé

This article aims at presenting the interest of high dose rate brachytherapy in the radiation treatment of prostatic adenocarcinoma. We will discuss successively the biological and dosimetric specificity of brachytherapy for this particular cancer. Afterwards, we will review the main phase II and III studies, the therapeutic indications in the daily practice from the evidence based medicine as well as the techniques of external beam radiation therapy for the same indications. Finally, the principal avenues of development will be discussed.

Titre traduit de la contribution	High dose rate prostate brachytherapy
langue originale	Français
Pages (de - à)	118-124
Nombre de pages	7
journal	Cancer/Radiotherapie
Volume	17
Numéro de publication	2
Les DOIs	https://doi.org/10.1016/j.canrad.2013.02.005
état	Publié - 1 avr. 2013

mots-clés

Brachytherapy
High dose rate
Prostate cancer

Accès au document

10.1016/j.canrad.2013.02.005

Autres fichiers et liens

Lien vers la publication dans Scopus

Contient cette citation

@article{93cb7d3c52444110a59cade3b1dc5875,

title = "Curieth{\'e}rapie prostatique de haut d{\'e}bit de dose",

abstract = "This article aims at presenting the interest of high dose rate brachytherapy in the radiation treatment of prostatic adenocarcinoma. We will discuss successively the biological and dosimetric specificity of brachytherapy for this particular cancer. Afterwards, we will review the main phase II and III studies, the therapeutic indications in the daily practice from the evidence based medicine as well as the techniques of external beam radiation therapy for the same indications. Finally, the principal avenues of development will be discussed.",

keywords = "Brachytherapy, High dose rate, Prostate cancer",

author = "P. Nickers and P. Blanchard and Hannoun-L{\'e}vi, {J. M.} and A. Bossi and O. Chapet and S. Gu{\'e}rif",

year = "2013",

month = apr,

day = "1",

doi = "10.1016/j.canrad.2013.02.005",

language = "Fran{\c c}ais",

volume = "17",

pages = "118--124",

journal = "Cancer/Radiotherapie",

issn = "1278-3218",

number = "2",

}

TY - JOUR

T1 - Curiethérapie prostatique de haut débit de dose

AU - Nickers, P.

AU - Blanchard, P.

AU - Hannoun-Lévi, J. M.

AU - Bossi, A.

AU - Chapet, O.

AU - Guérif, S.

PY - 2013/4/1

Y1 - 2013/4/1

N2 - This article aims at presenting the interest of high dose rate brachytherapy in the radiation treatment of prostatic adenocarcinoma. We will discuss successively the biological and dosimetric specificity of brachytherapy for this particular cancer. Afterwards, we will review the main phase II and III studies, the therapeutic indications in the daily practice from the evidence based medicine as well as the techniques of external beam radiation therapy for the same indications. Finally, the principal avenues of development will be discussed.

AB - This article aims at presenting the interest of high dose rate brachytherapy in the radiation treatment of prostatic adenocarcinoma. We will discuss successively the biological and dosimetric specificity of brachytherapy for this particular cancer. Afterwards, we will review the main phase II and III studies, the therapeutic indications in the daily practice from the evidence based medicine as well as the techniques of external beam radiation therapy for the same indications. Finally, the principal avenues of development will be discussed.

KW - Brachytherapy

KW - High dose rate

KW - Prostate cancer

UR - http://www.scopus.com/inward/record.url?scp=84878020551&partnerID=8YFLogxK

U2 - 10.1016/j.canrad.2013.02.005

DO - 10.1016/j.canrad.2013.02.005

M3 - Brève enquête

C2 - 23578898

AN - SCOPUS:84878020551

SN - 1278-3218

VL - 17

SP - 118

EP - 124

JO - Cancer/Radiotherapie

JF - Cancer/Radiotherapie

IS - 2

ER -